Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kalliopi Pafili

Showing results (1-10 of 39) with videos related to

Pageof 4
Sort By:
Molecular Metabolism|November 21, 2020
Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humansKalliopi Pafili, Michael Roden
Expert Opinion on Pharmacotherapy|May 3, 2014
Tofogliflozin: the road goes ever onKalliopi Pafili, Nikolaos Papanas
Expert Review of Medical Devices|December 9, 2014
Thermography in the follow up of the diabetic foot: best to weigh the enemy more mighty than he seemsKalliopi Pafili, Nikolaos Papanas
Expert Opinion on Pharmacotherapy|April 5, 2021
Considerations for single- versus multiple-drug pharmacotherapy in the management of painful diabetic neuropathyKalliopi Pafili, Nikolaos Papanas
Expert Opinion on Pharmacotherapy|January 22, 2015
Luseogliflozin and other sodium-glucose cotransporter 2 inhibitors: no enemy but time?Kalliopi Pafili, Nikolaos Papanas
Expert Opinion on Drug Delivery|March 26, 2014
The importance of patient compliance with insulin pens: how can a new user-friendly pen help?Kalliopi Pafili, Nikolaos Papanas
Current Opinion in Cardiology|April 28, 2018
New antihyperglycaemic agents and cardiovascular disease: let's be optimisticKalliopi Pafili, Manfredi Rizzo, Nikolaos Papanas
Current Opinion in Cardiology|June 8, 2015
The relationship between obstructive sleep apnoea and coronary heart diseaseKalliopi Pafili, Paschalis Steiropoulos, Nikolaos Papanas
Expert Opinion on Investigational Drugs|August 1, 2014
Gevokizumab in type 1 diabetes mellitus: extreme remedies for extreme diseases?Kalliopi Pafili, Nikolaos Papanas, Efstratios Maltezos
BMC Endocrine Disorders|February 24, 2021
Skin AGEs and diabetic neuropathyStella Papachristou, Kalliopi Pafili, Nikolaos Papanas
Pageof 4

Showing results (1-10 of 39) with videos related to

Sort By:
Pageof 4
Molecular Metabolism|November 21, 2020
Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humansKalliopi Pafili, Michael Roden
Expert Opinion on Pharmacotherapy|May 3, 2014
Tofogliflozin: the road goes ever onKalliopi Pafili, Nikolaos Papanas
Expert Review of Medical Devices|December 9, 2014
Thermography in the follow up of the diabetic foot: best to weigh the enemy more mighty than he seemsKalliopi Pafili, Nikolaos Papanas
Expert Opinion on Pharmacotherapy|April 5, 2021
Considerations for single- versus multiple-drug pharmacotherapy in the management of painful diabetic neuropathyKalliopi Pafili, Nikolaos Papanas
Expert Opinion on Pharmacotherapy|January 22, 2015
Luseogliflozin and other sodium-glucose cotransporter 2 inhibitors: no enemy but time?Kalliopi Pafili, Nikolaos Papanas
Expert Opinion on Drug Delivery|March 26, 2014
The importance of patient compliance with insulin pens: how can a new user-friendly pen help?Kalliopi Pafili, Nikolaos Papanas
Current Opinion in Cardiology|April 28, 2018
New antihyperglycaemic agents and cardiovascular disease: let's be optimisticKalliopi Pafili, Manfredi Rizzo, Nikolaos Papanas
Current Opinion in Cardiology|June 8, 2015
The relationship between obstructive sleep apnoea and coronary heart diseaseKalliopi Pafili, Paschalis Steiropoulos, Nikolaos Papanas
Expert Opinion on Investigational Drugs|August 1, 2014
Gevokizumab in type 1 diabetes mellitus: extreme remedies for extreme diseases?Kalliopi Pafili, Nikolaos Papanas, Efstratios Maltezos
BMC Endocrine Disorders|February 24, 2021
Skin AGEs and diabetic neuropathyStella Papachristou, Kalliopi Pafili, Nikolaos Papanas
Pageof 4